AutoLumo CLIA Tumor Markers, 100 Tests

The AutoLumo CLIA Tumor Marker Microparticles are high-sensitivity, high-specificity reagents developed for quantitative detection of tumor-associated biomarkers using chemiluminescent immunoassay (CLIA) technology.

These reagents are designed for use with the AutoLumo CLIA Analyzer Series, offering reliable and reproducible detection for clinical oncology, diagnostic, and research applications.

Each kit contains magnetic microparticle-based immunoreagents coated with specific antibodies for the target analyte, ensuring precise antigen–antibody binding and stable chemiluminescent signal generation.

The AutoLumo CLIA Tumor Marker panel provides comprehensive coverage of key tumor biomarkers used in the early detection, prognosis, and therapeutic monitoring of cancers such as liver, lung, breast, prostate, gastric, and ovarian malignancies.

Key Features

• High Sensitivity & Specificity: Advanced magnetic microparticle technology enhances detection accuracy.
• Wide Clinical Coverage: Includes tumor markers for digestive, respiratory, reproductive, and endocrine systems.
• Automated Compatibility: Designed for seamless use with AutoLumo CLIA Analyzers.
• Precision & Reliability: Ensures stable chemiluminescent reactions and reproducible results.
• Ready-to-Use Format: Pre-calibrated and quality-controlled reagents.
• Fast Turnaround: Enables high-throughput testing for routine diagnostic use.

Tumor Marker Microparticle Reagent List

Clinical Applications

• Oncology Screening and Monitoring:
  • AFP, CEA, CA19-9, CA125, CA15-3, CA72-4, CA242, CA50
  • Detection and follow-up of liver, gastrointestinal, ovarian, breast, and pancreatic cancers.
• Prostate Health Assessment:
  • tPSA, fPSA — Evaluation of prostate disorders and cancer risk.
• Lung and Respiratory Tumor Detection:
  • NSE, CYFRA 21-1, SCCA, ProGRP — Diagnosis and monitoring of lung carcinoma.
• Gastrointestinal Tumor Markers:
  • PG I, PG II, G-17, CA72-4 — Evaluation of gastric mucosal function and gastric cancer risk.
• Reproductive & Endocrine Tumors:
  • β-hCG, HE4 — Tumor and fertility-related marker testing.
• Iron Storage and Hematologic Malignancy Monitoring:
  • Ferritin, β2-MG — Assessment of anemia, liver disease, and malignancies.

Performance Characteristics

• Detection Method: Chemiluminescent Immunoassay (CLIA)
• Signal Detection: Magnetic microparticle-based sandwich immunoassay
• Measurement Range: Wide linear dynamic range with excellent correlation to reference assays
• Precision: Coefficient of variation (CV) ≤ 10%
• Storage: 2–8°C, protected from light
• Shelf Life: 12 months from manufacturing date

Unique Advantages

• Broad tumor marker portfolio for comprehensive cancer screening and monitoring.
• Optimized for AutoLumo CLIA analyzers ensuring precise performance and reproducibility.
• Stable and sensitive formulation designed for long-term reagent stability.
• Includes optional calibrators for traceability and accuracy in quantitative testing.
• Manufactured under strict quality standards for diagnostic consistency.

The AutoLumo CLIA Tumor Marker Microparticles Series provides a complete solution for tumor marker detection using chemiluminescent immunoassay technology.

With high accuracy, broad clinical coverage, and seamless automation compatibility, these reagents support early cancer detection, diagnosis, and therapeutic monitoring across multiple organ systems.

An ideal reagent solution for clinical chemistry laboratories, hospitals, and research institutions using AutoLumo CLIA systems for comprehensive tumor marker profiling.